Does the primary tumour location affect the prognosis of patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?

Haipeng Chen†, Sicheng Zhou†, Jianjun Bi, Qiang Feng, Zheng Jiang, Jianping Xu, Wei Pei*, Jianwei Liang, Zhixiang Zhou and Xishan Wang

Abstract

Background: The impact of primary tumour location on the prognosis of patients with peritoneal metastasis (PM) arising from colorectal cancer (CRC) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is rarely discussed, and the evidence is still limited.

Methods: Patients with PM arising from CRC treated with CRS and HIPEC at the China National Cancer Center and Huanxing Cancer Hospital between June 2017 and June 2019 were systematically reviewed. Clinical characteristics, pathological features, perioperative parameters, and prognostic data were collected and analysed.

Results: A total of 70 patients were divided into two groups according to either colonic or rectal origin (18 patients in the rectum group and 52 patients in the colon group). Patients with PM of a colonic origin were more likely to develop grade 3–4 postoperative complications after CRS+HIPEC (38.9% vs 19.2%, \( P = 0.094 \)), but this difference was not statistically significant. Patients with colon cancer had a longer median overall survival (OS) than patients with rectal cancer (27.0 vs 15.0 months, \( P = 0.011 \)). In the multivariate analysis, the independent prognostic factors of reduced OS were a rectal origin (HR 2.15, 95% CI 1.15–4.93, \( P = 0.035 \)) and incomplete cytoreduction (HR 1.99, 95% CI 1.06–4.17, \( P = 0.047 \)).

Conclusion: CRS is a complex and potentially life-threatening procedure, and we suggest that the indications for CRS+HIPEC in patients with PM of rectal origin be more restrictive and that clinicians approach these cases with caution.

Keywords: Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy, Primary tumour location, Prognosis
Introduction

Colorectal cancer (CRC) is one of the most common malignant tumours in the world, and its morbidity and mortality rank third and fourth, respectively [1–3]. Among patients with CRC, 5–15% have synchronous peritoneal metastasis (PM), and the incidence of metachronous PM is as high as 20 to 50% [4]. PM arising from CRC is an indicator of terminal stage disease and carries a very poor prognosis. In the past, palliative surgery and systemic chemotherapy were mostly adopted, but the therapeutic effect was poor, and the median survival time was only 5 to 7 months [5]. Currently, cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown good clinical efficacy in the comprehensive treatment of various malignant peritoneal diseases, including CRC, ovarian cancer, and appendiceal mucous adenocarcinoma, and it has been considered a standard therapy for prolonging the survival of patients with PM arising from CRC [6–10].

At present, most of the extant literature has demonstrated that a high peritoneal cancer index (PCI), incomplete cytoreduction, young age, lymphovascular invasion, and postoperative complications are poor prognostic factors after CRS+HIPEC [11–15]. It has been well established that different primary tumour locations have different biological behaviours and prognosis [16–19]. However, previous studies have only compared the prognostic differences between the colonic origin and rectal origin of the primary tumour; the impact of the primary tumour location on the prognosis of patients with PM arising from CRC after CRS+HIPEC is rarely discussed, and clinical evidence remains scarce [20]. It is highly desirable to optimize patient selection to include only those who are most likely to benefit from this complex and potentially life-threatening procedure. Therefore, the aim of this study was to explore the impact of primary tumour location according to colon or rectal origin on the prognosis of patients with PM arising from CRC treated with CRS+HIPEC in our institution.

Methods
Study design and patients

The study protocol was approved by the Ethics Committee of the Cancer Hospital, Chinese Academy of Medical Sciences (NCC2017-YZ-026, October 17, 2017). The data of all patients with synchronous or metachronous PM arising from CRC who underwent CRS with HIPEC at the National Cancer Center and Huanxing Cancer Hospital were retrospectively obtained from a prospectively maintained database between June 2017 and June 2019. The inclusion criteria of this study were as follows: (1) patients with PM of a colonic or rectal origin, (2) pathologically confirmed PM after operation, and (3) age between 18 and 75 years. The exclusion criteria were as follows: (1) complications with the liver, lung, or other sites of distant metastasis; (2) history of other malignant tumours; and (3) malignant tumour of appendix origin. According to the location of the primary tumour, all enrolled patients were divided into a colon group (n = 52) and a rectal group (n = 18). The colon was regarded as the caecum, ascending colon, transverse colon descending colon, and sigmoid colon, while the rectum was regarded as the intestinal canal below 15 cm from the anal margin.

Demographic and clinical variables, as well as perioperative and long-term survival outcomes, were collected and compared. All enrolled patients underwent a routine preoperative evaluation, which included laboratory examinations, abdominal contrast-enhanced computed tomography, pelvic magnetic resonance imaging, and fluorodeoxyglucose positron emission tomography, to assess their general condition. According to the Sugarbaker/Jacquet classification, peritoneal disease burden and the completeness of cytoreduction were assessed using the PCI and completeness of cytoreduction (CC) score, respectively [21, 22]. All postoperative complications were graded using the Clavien-Dindo classification according to the treatment received [23].

Surgical technique

The surgical techniques adopted at our institution have been previously described [9, 21]. Briefly, three outflow drains and one inflow drain were routinely placed in the abdomen in preparation for HIPEC. HIPEC was administered in a closed fashion, with oxaliplatin (200 mg/m²) and raltitrexed (3 mg/m²), combined with or without lobaplatin (50 mg/m²). Then, patients were treated with a mixed solution of chemotherapy agents and 31 of saline solution infused into the abdominal and pelvic cavity for 60 min at 42–43 °C. Next, two additional HIPEC procedures were performed in the ward on the second and fourth days after surgery in both groups. Furthermore, two surgical specialists with more than 20 years of experience in gastrointestinal surgery performed the operations at the two centres, and the HIPEC technique and postoperative treatment were identical.

Statistical analysis

Data between two groups were analysed with SPSS 24.0 software (IBM, Armonk, NY, USA). Categorical data are expressed as percentages and were
compared using the $\chi^2$ test or Fisher’s exact test as appropriate. Continuous data are expressed as the mean ± standard deviation and were compared using Student’s $t$-test and the Mann-Whitney $U$ test for independent values with normally and nonnormally distributed values, respectively. Overall survival (OS) was defined as the time from surgery to the time of death from any cause or July 31, 2020, whichever came first. The Kaplan-Meier method and log-rank test were utilized to evaluate associations between individual factors and OS. Variables found to be significant ($P$ value < 0.20) in the univariate analysis were incorporated into the multivariate analysis to identify independent predictors of OS. A $P$ value < 0.05 was considered statistically significant.

**Results**

**Demographic and clinical variables**

A total of 70 patients with PM of CRC origin who underwent CRS+HIPEC were included in the present study. Of these patients, 18 (25.7%) had rectal cancer and 52 (74.3%) had colon cancer. The mean age of all patients was 54.5 years, and the majority (55.7%) of patients in the study were male. Patients were well balanced across the two groups in terms of age, sex, body mass index (BMI), preoperative comorbidity, preoperative chemotherapy, presentation of PM, preoperative CEA level, preoperative CA19-9 level, histology, tumour grade, adjuvant chemotherapy, BRAF status, and MSI ($P > 0.05$) (Table 1).

**Operative and perioperative data**

The operative details and postoperative courses are listed in Table 2. The mean PCI of all enrolled patients was 11.1, and complete cytoreduction (CC 0–1) was achieved in most patients (68.6%). Patients in both groups had comparable mean operative times (255.5 vs 257.4 min, $P = 0.922$) and estimated blood loss (98.9 vs 130.2 ml, $P = 0.301$). Patients in the rectal group were more likely to undergo colostomy or ileostomy (66.7% vs 30.8%, $P = 0.007$) during the operation. Compared with patients in the colon group, patients in the rectum group were more likely to develop grade 3–4 postoperative complications (38.9% vs 19.2%, $P = 0.094$), but this difference was not statistically significant. Illus (7.1%) and pelvic cavity abscesses (7.1%) were the most common postoperative complications, followed by anastomotic leakage (5.7%), wound infection (2.9%), pneumonia (5.4%), pleural effusion (1.4%), cardiac arrhythmia (1.4%), urinary retention (1.4%), and rectovaginal leakage (1.4%). Two patients (2.9%) required revision surgery due to extensive pelvic cavity abscesses and postoperative bleeding.

**Overall survival**

The median estimated follow-up period from CRS/HIPEC for the study population was 28 months. The median survival period for all patients was 25 months, and the estimated 1-, 2- and 3-year OS rates for the entire cohort were 72.6%, 51.4%, and 40.1%, respectively (Fig. 1). The median OS for those with colon cancer was 27 months compared with 15 months for those with rectal cancer ($P = 0.011$) (Fig. 2). The median OS from CRS+HIPEC in patients undergoing incomplete cytoreduction (CC 2–3) was 12 months, while the median OS was not reached in patients undergoing complete cytoreduction (CC 0–1) (Fig. 3). Variables with $P < 0.20$ in the univariate regression analysis, such as increasing PCI (HR 1.09, 95% CI 1.03–1.14, $P = 0.002$), rectal origin (HR 2.54, 95% CI 1.24–5.18, $P = 0.011$), incomplete cytoreduction (HR 3.49, 95% CI 1.77–6.87, $P < 0.001$), and HIPEC regimen (HR 0.63, 95% CI 0.31–1.28, $P = 0.199$), were included in the multivariate analysis. In the multivariate analysis, independent prognostic factors of reduced OS were rectal origin (HR 2.15, 95% CI 1.15–4.93, $P = 0.035$) and incomplete cytoreduction (HR 1.99, 95% CI 1.06–4.17, $P = 0.047$) (Table 3).

**Discussion**

Primary tumour location is recognized as an important prognostic factor for metastatic CRC, and it is also a selection factor for the administration of different targeted medicines [16–19]. However, the impact of primary tumour location on the prognosis of CRC patients undergoing CRS+HIPEC due to PM is rarely discussed, so the available evidence remains limited [20]. Therefore, we conducted this study to elucidate the differences in different primary tumour locations among patients with PM arising from CRC and focused on the significant impacts of these differences on perioperative outcomes and long-term prognosis.

In the present study, 70 enrolled patients were divided into two groups according to the origin of the primary tumour: the colon group (52 patients) and the rectal group (18 patients). The average age of the patients included in this study was only 54.5 years old, and only 25.7% of patients had comorbidities before surgery. This may be due to the aggressive tumour behaviour observed in young patients; these tumours show high invasiveness and a predilection towards distant metastases in regions such as the peritoneum in this population. Our results revealed that patients with colon cancer-derived PM
had a longer median survival after CRS+HIPEC (27.0 vs 15.0 months, \( P = 0.011 \)), and primary tumour location remained an independent predictor of OS (HR 2.15, 95% CI 1.15–4.93, \( P = 0.035 \)). In 2018, Tonello et al. [17] published a paper in which they analysed survival in patients with colorectal PM

Table 1 Patient characteristics

| Characteristics          | Total (n = 70) | Rectum (n = 18) | Colon (n = 52) | \( P \) |
|--------------------------|---------------|----------------|---------------|------|
| Age at operation (years, mean ± SD) | 54.5 ± 11.6   | 52.7 ± 12.2    | 55.2 ± 11.6   | 0.451|
| Sex (%)                  |               |                |               | 0.571|
| Male                     | 39 (55.7)     | 9 (50.0)       | 30 (57.7)     |      |
| Female                   | 31 (44.3)     | 9 (50.0)       | 22 (42.3)     |      |
| Body mass index (kg/m², mean ± SD) | 22.7 ± 3.6    | 23.8 ± 3.9     | 22.8 ± 3.5    | 0.665|
| Comorbidity              | 18 (25.7)     | 4 (22.2)       | 14 (26.9)     | 0.936|
| Hypertension             | 10 (14.3)     | 2 (11.1)       | 8 (15.4)      |      |
| Diabetes                 | 6 (8.6)       | 2 (11.1)       | 4 (7.7)       |      |
| Coronary heart disease   | 2 (2.9)       | 1 (5.5)        | 1 (1.9)       |      |
| Arrhythmia               | 4 (5.7)       | 0 (0)          | 4 (7.7)       |      |
| Others                   | 6 (8.6)       | 1 (5.5)        | 5 (9.6)       |      |
| Preoperative chemotherapy (%) |             |                |               | 0.477|
| Presence                 | 30 (42.9)     | 9 (50.0)       | 21 (40.4)     |      |
| Absence                  | 40 (57.1)     | 9 (50.0)       | 31 (59.6)     |      |
| Presentation of PM (%)   |               |                |               | 0.118|
| Synchronous              | 42 (60.0)     | 8 (44.4)       | 34 (65.4)     |      |
| Metachronous             | 28 (40.0)     | 10 (55.6)      | 18 (34.6)     |      |
| T stage                  |               |                |               | 0.954|
| T1–T2                    | 5 (11.9)      | 1 (12.5)       | 4 (11.8)      |      |
| T3–T4                    | 37 (88.1)     | 7 (87.5)       | 30 (88.2)     |      |
| N stage                  |               |                |               | 0.482|
| N0                       | 2 (4.8)       | 0 (0)          | 2 (5.9)       |      |
| N1–N2                    | 40 (95.2)     | 8 (100.0)      | 32 (94.1)     |      |
| Preoperative CEA level (ng, mean ± SD) | 31.9 ± 61.5  | 16.6 ± 27.2    | 37.2 ± 69.8   | 0.290|
| Preoperative CA19-9 level (ng, mean ± SD) | 75.4 ± 93.3  | 69.2 ± 112.4   | 77.5 ± 88.4   | 0.780|
| Histology (%)            |               |                |               | 0.275|
| Adenocarcinoma           | 43 (61.4)     | 13 (72.2)      | 30 (57.7)     |      |
| Mucinous                 | 27 (38.6)     | 5 (27.8)       | 22 (42.3)     |      |
| Tumour grade             |               |                |               | 0.370|
| Moderate                 | 26 (37.1)     | 8 (44.4)       | 17 (32.7)     |      |
| Poor                     | 44 (62.9)     | 10 (55.6)      | 35 (67.3)     |      |
| Adjuvant chemotherapy    |               |                |               | 0.924|
| Presence                 | 55 (78.6)     | 14 (77.8)      | 41 (78.8)     |      |
| Absence                  | 15 (21.4)     | 4 (22.2)       | 11 (21.2)     |      |
| BRAF status              |               |                |               | 0.809|
| Mutation                 | 13 (18.6)     | 3 (16.7)       | 10 (19.2)     |      |
| No mutation              | 57 (81.4)     | 15 (83.3)      | 42 (80.8)     |      |
| MSI                      |               |                |               | 0.961|
| MSI-H                    | 8 (11.4)      | 2 (11.1)       | 6 (11.5)      |      |
| MSS                      | 62 (88.6)     | 16 (88.9)      | 46 (88.5)     |      |

Note: SD standard deviation, PM standard peritoneal metastasis
treated with CRS+HIPEC and reported that PM of a rectal origin was associated with worse long-term survival outcomes than PM of a colonic origin (median OS 47.8 vs 22.0 months, \( P = 0.008 \)). Similarly, Da Silva et al. [16] also demonstrated that the median survival in patients with PM of a colonic origin was significantly better than that in patients with PM of a rectal origin (35.0 vs 17.0 months). The above research results are basically consistent with our findings.

Several theories have been proposed to explain this difference in terms of the prognosis of PM of a rectal origin. Anatomically, rectal tumours are located in a narrow pelvic cavity, which makes resection of the primary tumour and pelvic peritoneal metastasis difficult; therefore, achieving complete cytoreduction is a challenge, and the possibility of a residual tumour is increased [24]. Low-middle rectal cancer (under the peritoneum) increases the risk of perforating the rectal wall, which is thicker than the colon wall; the thickness of the rectal wall is the reason underlying the more biologically aggressive disease characteristics observed in this population [16]. Finally, patients with peritoneal metastases originating from rectal cancer are more likely to develop postoperative complications, and the occurrence of

### Table 2 Operative and perioperative data

| Characteristic                  | Total (n = 70) | Rectum (n = 18) | Colon (n = 52) | \( P \) |
|--------------------------------|---------------|----------------|--------------|-----|
| Operative method               |               |                |              |     |
| Laparoscopic surgery           | 14 (20.0)     | 5 (27.8)       | 9 (17.3)     | 0.538 |
| Open surgery                   | 56 (80.0)     | 13 (72.2)      | 43 (82.7)    |     |
| HIPEC regimen                  |               |                |              | 0.000 |
| Lobaplatin + oxaliplatin + raltitrexed | 32 (45.7) | 8 (44.4)       | 24 (46.2)    |     |
| Oxaliplatin + raltitrexed      | 38 (54.3)     | 10 (55.6)      | 28 (53.8)    |     |
| Colostomy or ileostomy         |               |                |              | 0.007 |
| Presence                       | 28 (40.0)     | 12 (66.7)      | 16 (30.8)    |     |
| Absence                        | 42 (60.0)     | 6 (33.3)       | 36 (69.2)    |     |
| PCI score (mean ± SD)          | 11.1 ± 6.0    | 11.7 ± 6.9     | 10.8 ± 5.8   | 0.600 |
| Presence of ascites            |               |                |              | 0.693 |
| Presence                       | 30 (42.9)     | 7 (38.9)       | 23 (44.2)    |     |
| Absence                        | 40 (57.1)     | 11 (61.1)      | 29 (55.8)    |     |
| CC score                       |               |                |              | 0.168 |
| CC 0–1                         | 48 (68.6)     | 10 (55.5)      | 38 (73.1)    |     |
| CC 2–3                         | 22 (31.4)     | 8 (44.5)       | 14 (26.9)    |     |
| Operative time, min (mean ± SD)| 256.9 ± 66.0  | 255.5 ± 83.5   | 257.4 ± 60.4 | 0.922 |
| Estimated blood loss, ml (mean ± SD)| 122.1 ± 109.2 | 98.9 ± 82.9   | 130.2 ± 117.5 | 0.301 |
| Postoperative complications    | 17 (24.3)     | 7 (38.9)       | 10 (19.2)    | 0.094 |
| (grades III, IV)               |               |                |              |     |
| Postoperative bleeding         | 2 (2.9)       | 1 (5.6)        | 1 (1.9)      |     |
| Anastomotic leakage            | 4 (5.7)       | 2 (11.1)       | 2 (3.8)      |     |
| Pelvic cavity abscess          | 5 (7.1)       | 2 (11.1)       | 3 (5.8)      |     |
| Ileus                          | 5 (7.1)       | 2 (11.1)       | 3 (5.8)      |     |
| Pneumonia                      | 1 (1.4)       | 1 (5.6)        | 0 (0)        |     |
| Pleural effusion               | 1 (1.4)       | 1 (5.6)        | 0 (0)        |     |
| Cardiac arrhythmia             | 0 (0)         | 0 (0)          | 1 (1.9)      |     |
| Wound infection                | 2 (2.9)       | 1 (5.6)        | 1 (1.9)      |     |
| Urinary retention              | 1 (1.4)       | 0 (0)          | 1 (1.9)      |     |
| Rectovaginal leakage           | 1 (1.4)       | 0 (0)          | 1 (1.9)      |     |
| Postoperative hospital stay,   | 14.6 ± 5.3    | 15.4 ± 4.7     | 14.3 ± 5.6   | 0.380 |
| days (mean ± SD)               |               |                |              |     |
| Re-operation                   | 2 (2.9)       | 1 (5.6)        | 1 (5.6)      | 1.000 |
| Mortality                      | 0 (0)         | 0 (0)          | 0 (0)        | –    |

Note: HIPEC, HIPEC standard hyperthermic intraperitoneal chemotherapy; PCI, PCI standard peritoneal cancer index; CC, CC standard complete cytoreduction.
complications negatively affects the overall condition of the patients, as well as subsequent adjuvant treatment, and thus has an impact on prognosis. However, the above mechanisms are limited to only a theoretical level; additional studies are needed in the future to further explain the differences in the prognosis of patients with PM arising from different sites of origin at the genetic level.

Close attention has been given to the morbidity and mortality associated with the CRS+HIPEC procedure. Our institution confirmed that the grade 3–4 morbidity and mortality rates after CRS+HIPEC were 24.3% and 0%, respectively, which is basically consistent with the results reported by international centres [9, 14, 25–27]. Notably, we also found that patients with PM of a rectal origin were more likely to develop grade 3–4 postoperative complications after CRS+HIPEC than patients with PM of a colonic origin (38.9% vs 19.2%, \(P = 0.094\)), but this difference was not statistically significant. CRS is an originally complex and potentially life-threatening procedure. Due to the special anatomical location of rectal tumours, the narrow operating space further increases the difficulty of CRS.

The limitations of this study are those inherent to a single institution with a limited sample size, which may underlie some of the differences observed between the rectal group and the colon group. Second, this study was also limited by its retrospective nature, which makes it difficult to control for bias and confounders. Therefore, we recommend that clinicians exert caution when making any definitive conclusions. Multicentre prospective randomized controlled studies are required to further verify our results.

**Conclusion**

Patients with PM of a rectal origin were more likely to develop postoperative complications after CRS+HIPEC, which is indicative of a poor prognosis. We suggest that the indications for CRS+HIPEC in patients with PM of rectal origin should be more restrictive and cautious.

**Abbreviations**

PM: Peritoneal metastasis; CRC: Colorectal cancer; CRS: Cytoreductive surgery; HIPEC: Hyperthermic intraperitoneal chemotherapy; PCI: Peritoneal cancer index; CC: Completeness of cytoreduction; OS: Overall survival; BMI: Body mass index

**Acknowledgements**

Not applicable.
Available from the corresponding author upon reasonable request. The datasets generated and/or analysed during the current study are not publicly available because the data are confidential patient data but are not available from the corresponding author upon reasonable request.

Availability of data and materials

Declarations

Ethics approval and consent to participate

The Ethics Committee of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, approved this study. Prior written informed consent was obtained from all study participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 15 June 2021 Accepted: 12 August 2021

Published online: 26 August 2021

References

1. Chen WQ, Zheng RS, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. https://doi.org/10.3322/caac.21338.

2. Wang W, Lu K, Wang L, Jing H, Pan W, Huang S, et al. Comparison of non-schistosomal colorectal cancer and schistosomal colorectal cancer. World J Surg Oncol. 2020;18(1):149. https://doi.org/10.1186/s12957-020-01925-5.

3. Liao CK, Yu YL, Lin YC, Hsu YJ, Chen YJ, Chiang JM, et al. Prognostic value of the C-reactive protein to albumin ratio in colorectal cancer: an updated systematic review and meta-analysis. World J Surg Oncol. 2021;19(1):1139. https://doi.org/10.1186/s12957-021-02253-y.

4. van Gestel YR, de Hingh IH, van Herk-Sukel MP, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol. 2014;38(4):448–54. https://doi.org/10.1016/j.canep.2014.04.004.

5. Kerscher AG, Chua TC, Gasser M, Maeder U, Kunzmann V, Isbert C, et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer. 2013;108(7):1432–9. https://doi.org/10.1038/bjc.2013.82.

6. Bushati M, Rovers KP, Sommariva A, Sugarbaker PH, Morris DL, Yonemura Y, et al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2018;44(12):1942–8. https://doi.org/10.1016/j.ejso.2018.07.003.

7. Cazin PH, Mahteme H, Splang N, Syk I, Fedin J, Torkild M, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer. 2016;53:155–62. https://doi.org/10.1016/j.ejca.2015.09.017.

8. Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40. https://doi.org/10.1056/NEJMoa1708618.

9. Klaver CE, Wissink DD, Punt CJA, Snaebjornsson P, Crezee J, Balbers AGJ, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4(10):761–70. https://doi.org/10.1016/S2468-1253(19)30239-0.

10. Quenet F, Elias D, Rocca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC); PRODIGE 7. J Clin Oncol. 2018;36:118.

11. Zhou S, Feng Q, Zhang J, Zhou H, Jiang Z, Liu Z, et al. High-grade postoperative complications affect survival outcomes of patients with colorectal cancer peritoneal metastesises treated with cytoreductive surgery and hyperthermic Intraperitoneal chemotherapy. BMC Cancer. 2021;21(1):41. https://doi.org/10.1186/s12885-020-02756-7.

12. Masalou D, Benizri E, Chevallier A, Duranton-Tanneur V, Pedetour F, Benchimol D, et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017;212(3):377–87. https://doi.org/10.1016/j.amjsurg.2016.03.008.

13. Sipok A, Sardi A, Nieroda C, et al. Comparison of survival in patients with isolated peritoneal carcinomatosis from colorectal cancer treated with cytoreduction and melphalan or mitomycin-C as hyperthermic intraperitoneal chemotherapy agent. Int J Surg Oncol. 2018;2018:1920276.

14. Soliani L, D’Acapito F, Passardi A, et al. Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study. World J Surg Oncol. 2019;17(1):58. https://doi.org/10.1186/s12957-019-1602-z.

15. Creasy JM, Sadot E, Koerkamp BG, Chou JF, Gonen M, Kemeny NE, et al. The impact of primary tumor location on long-term survival in patients undergoing hepatic resection for metastatic colon cancer. Ann Surg Oncol. 2018;25(2):431–8. https://doi.org/10.1245/s10434-017-6284-x.

16. da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203(6):878–86. https://doi.org/10.1016/j.jamcollsurg.2006.08.024.

17. Tonello M, Ortega-Gomez P, Alonso-Casado O, Torres-Mesa P, Guíñez G, Gonzalez-Moreno S. Peritoneal carcinomatosis arising from rectal or colonic adenocarcinoma treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). two different diseases. Clin Transl Oncol. 2020;18(10):1266–73. https://doi.org/10.1007/s12094-018-1857-9.

18. Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43. https://doi.org/10.1200/JO0034-017-6254-x.

19. Zhang RX, Ma WJ, Gu YT, Zhang TQ, Huang ZM, Lu ZH, et al. Primary tumor location as a predictor of the benefit of palliative resection for colorectal cancer with unresectable metastasis. World J Surg Oncol. 2017;15(1):138. https://doi.org/10.1186/s12957-017-1198-0.

20. Kelly KJ, Alyayadah M, Vaida F, Veerapong J, Baumgartner JM, Patel S, et al. Does primary tumor side matter in patients with metastatic colon cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol. 2019;26(5):1421–7. https://doi.org/10.1245/s10434-019-07255-5.

21. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74. https://doi.org/10.1007/978-1-4613-1247-5_23.

22. Koh JL, Yan TT, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16(2):327–33. https://doi.org/10.1245/s10434-008-0234-2.

23. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–21; discussion 220–1. https://doi.org/10.1097/01.sla.0000133046.83549.ae.

24. Sugarbaker PH. Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer. World J Gastroenterol. 2014;20(28):9286–91. https://doi.org/10.3748/wjg.v20.i28.9286.

25. Woeste MR, Philips P, Egger ME, et al. Optimal perfusion chemotherapy: a prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer. J Surg Oncol. 2020; [published online ahead of print, 2020 Apr 1].

26. Beal EW, Suarez-Kelly LP, Kimbergh OW, Johnston FM, Greer J, Abbott DE, et al. Impact of neoadjuvant chemotherapy on the outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi-institutional retrospective review. J Clin Med. 2020;9(3):748. https://doi.org/10.3390/jcm9030748.
27. Wong JSM, Tan GHC, Chia CS, Ong J, Ng WY, Teo MCC. The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2020;18(1):10. https://doi.org/10.1186/s12957-020-1784-4.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.